B cells and cancer: To B or not to B?
Journal
Journal of Experimental Medicine
Journal Volume
218
Journal Issue
1
Date Issued
2021
Author(s)
Abstract
Whereas T cells have been considered the major immune cells of the tumor microenvironment able to induce tumor regression and control cancer clinical outcome, a burst of recent publications pointed to the fact that B cells may also play a prominent role. Activated in germinal centers of tertiary lymphoid structures, B cells can directly present tumor-associated antigens to T cells or produce antibodies that increase antigen presentation to T cells or kill tumor cells, resulting in a beneficial clinical impact. Immune complexes can also increase inflammation, angiogenesis, and immunosuppression via macrophage and complement activation, resulting in deleterious impact. ? 2020 Fridman et al.
SDGs
Other Subjects
tumor antigen; angiogenesis; B lymphocyte; complement activation; germinal center; human; immunosuppressive treatment; inflammation; macrophage; malignant neoplasm; nonhuman; priority journal; Review; T lymphocyte; tertiary lymphoid structure; tumor immunology; animal; B lymphocyte; immunology; neoplasm; neovascularization (pathology); pathology; tumor microenvironment; vascularization; Animals; Antigens, Neoplasm; B-Lymphocytes; Complement Activation; Humans; Inflammation; Macrophages; Neoplasms; Neovascularization, Pathologic; T-Lymphocytes; Tumor Microenvironment
Publisher
Rockefeller University Press
Type
review